Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00075478
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:34.536076+00:00
Published At
2014-05-19T00:00:00+00:00
Record Updated At
2017-05-15
Results Posted At
2014-05-19
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Acute Lymphoblastic Leukemia in Remission", "Acute Myeloid Leukemia in Remission", "Aggressive Non-Hodgkin Lymphoma", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Diffuse Large B-Cell Lymphoma", "Hematopoietic and Lymphoid Cell Neoplasm", "Indolent Non-Hodgkin Lymphoma", "Mantle Cell Lymphoma", "Myelodysplastic/Myeloproliferative Neoplasm", "Plasma Cell Myeloma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hodgkin Lymphoma", "Waldenstrom Macroglobulinemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2017-05-15"
protocolSection.identificationModule.nctId
"NCT00075478"
protocolSection.identificationModule.officialTitle
"A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2014-05-19"

Study condition terms

  • Acute Lymphoblastic Leukemia in Remission (protocolSection.conditionsModule.conditions)
  • Acute Myeloid Leukemia in Remission (protocolSection.conditionsModule.conditions)
  • Aggressive Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (protocolSection.conditionsModule.conditions)
  • Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Hematopoietic and Lymphoid Cell Neoplasm (protocolSection.conditionsModule.conditions)
  • Indolent Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Mantle Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Myelodysplastic/Myeloproliferative Neoplasm (protocolSection.conditionsModule.conditions)
  • Plasma Cell Myeloma (protocolSection.conditionsModule.conditions)
  • Refractory Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Waldenstrom Macroglobulinemia (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.